Media headlines about Supernus Pharmaceuticals (NASDAQ:SUPN) have been trending somewhat positive recently, according to Accern Sentiment. Accern scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Supernus Pharmaceuticals earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave news stories about the specialty pharmaceutical company an impact score of 45.8506121180333 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Use of charts to make investment decisions about Supernus Pharmaceuticals, Inc. (SUPN) – Wall Street Morning (wallstreetmorning.com)
- Supernus Pharma (SUPN) Proposed Private Offering of $350 Million … – StreetInsider.com (streetinsider.com)
- Supernus Pharma (SUPN) Proposed Private Offering of $350 Million of Convertible Senior Notes (streetinsider.com)
- Supernus Announces Proposed Private Offering of $350 Million of Convertible Senior Notes (finance.yahoo.com)
- Supernus Pharmaceuticals (SUPN) Rating Increased to Buy at BidaskClub (americanbankingnews.com)
Several equities research analysts have commented on SUPN shares. Janney Montgomery Scott raised shares of Supernus Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $47.00 price objective on the stock in a report on Monday, December 4th. Zacks Investment Research downgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, January 12th. B. Riley upped their price objective on shares of Supernus Pharmaceuticals from $50.00 to $54.00 and gave the company a “buy” rating in a report on Thursday, December 28th. BidaskClub downgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, February 1st. Finally, ValuEngine downgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Two research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $51.36.
Shares of Supernus Pharmaceuticals (SUPN) traded down $1.75 during trading on Wednesday, hitting $43.15. 1,779,173 shares of the stock were exchanged, compared to its average volume of 606,947. Supernus Pharmaceuticals has a 52-week low of $26.85 and a 52-week high of $50.04. The stock has a market capitalization of $2,210.00, a P/E ratio of 34.25 and a beta of 1.06.
Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.02. The firm had revenue of $80.40 million for the quarter, compared to the consensus estimate of $78.74 million. Supernus Pharmaceuticals had a net margin of 18.95% and a return on equity of 28.07%. The firm’s revenue was up 41.5% on a year-over-year basis. analysts expect that Supernus Pharmaceuticals will post 1.87 earnings per share for the current fiscal year.
In related news, VP Victor Vaughn sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $42.04, for a total value of $630,600.00. Following the transaction, the vice president now directly owns 24,344 shares in the company, valued at $1,023,421.76. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Padmanabh P. Bhatt sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 17th. The stock was sold at an average price of $44.98, for a total transaction of $899,600.00. Following the completion of the transaction, the vice president now owns 32,500 shares in the company, valued at $1,461,850. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 165,750 shares of company stock worth $7,133,973. 6.70% of the stock is owned by company insiders.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.